MiNK Therapeutics achieved significant clinical milestones in Q3 2025, demonstrating promising survival outcomes for patients with relapsed or refractory cancers through its investigational AGENT-797 therapy, while strengthening collaborations and enhancing its operational independence.

• AGENT-797 therapy demonstrated a remarkable median overall survival of approximately 23 months in patients treated for resistant solid tumors, far exceeding expectations for this patient cohort.
• The therapy exhibited a strong safety profile, with no major toxicities observed, underscoring its potential as a viable treatment option in challenging cancer cases.
• MiNK has established strategic partnerships with the University of Wisconsin and received significant funding support for advancing its iNKT cell therapy platform, aimed at improving outcomes post-stem cell transplantation.
• The company's leadership was strengthened with the appointment of Dr. John Holcomb to the Board, enhancing its strategic vision in clinical development and partnerships.
• MiNK Therapeutics is positioned as a leader in the allogeneic iNKT cell space, bolstered by its scientific advancements and disciplined capital utilization.